WOBURN, Mass. and VEDBAEK, Denmark, Aug. 12 /PRNewswire/ -- AdvanDx today announced
Every year, an estimated 100,000 patients develop bloodstream infections (BSI) due to Gram-negative pathogens, mainly E. coli, K. pneumoniae and P. aeruginosa. Patients afflicted by these serious infections spend an average of 15 days in the hospital, suffer mortality rates as high as 40% and cost institutions between $40,000 to $60,000 per case.(1,2) These grim statistics are due in part to Gram-negative bacteria's increasing resistance to a multitude of antibiotic agents, especially in P. aeruginosa and increasingly in K. pneumoniae, creating complex therapy decisions for clinicians. Treatment challenges are further compounded by conventional laboratory testing methods that take 24-48 hours or longer to identify the causative pathogen, forcing clinicians to treat patients empirically. This empirical antibiotic coverage can lead to both unnecessary treatment with broad-spectrum antibiotics as well as inadequate treatment if highly virulent and resistant pathogens are not suspected and covered for.
Studies show that providing a 24 hours "head start" on appropriate, narrow-spectrum therapy for Gram-negative bloodstream infections may improve clinical outcomes, reduce antibiotic resistance rates and reduce the incidences of adverse events.(3,4) GNR Traffic Light PNA FISH will enable microbiology labs to provide clinicians rapid, accurate Gram-negative pathogen identification results in hours, instead of days.
"The GNR Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections," said Thais T. Johansen, President and CEO of AdvanDx. "This latest PNA FISH test provides another tool to help laboratories and clinicians improve antibiotic selection, care and outcomes for critically ill patients with bloodstream infections," Johansen concluded.
About Bloodstream Infections
Every year, close to 875,000 patients in the United States contract bloodstream infections, leading to over 150,000 deaths and $12 billion in patient care costs.(5,6) The infection is detected when a culture of the patient's blood (i.e. a blood culture) turns positive with bacteria or yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.
AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.
AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.
For more information visit www.AdvanDx.com
Subscribe to our Free Newsletters!